Is romiplostim still on patent in the UK, and when would it expire?
I don’t have enough UK patent/exclusivity data in the provided information to say whether romiplostim is currently “off patent” in the UK or the exact expiry date that would let biosimilars enter.
If you want the most direct answer for the UK, you’ll need the specific product (brand name) and either:
- the UK patent numbers covering romiplostim in the UK, or
- the UK/EMA market authorisation details that determine data/marketing protection and any supplementary protection certificates (SPCs).
What “off patent” usually means for romiplostim in the UK
In practice, “off patent” for a biologic like romiplostim depends on whether any form of protection still blocks biosimilar entry, which can include:
- patent protection on the active substance and/or specific claims,
- supplementary protection (SPCs) tied to marketing authorisation dates,
- data exclusivity and other regulatory exclusivities that can delay approval even if some patents expire.
Because biosimilars require regulatory approval, you can sometimes see a gap where patents are no longer enforceable but exclusivity still delays market entry.
How can you check if biosimilars can launch in the UK for romiplostim?
To determine whether romiplostim is effectively “off patent” for UK launch, you can look for:
- UK patent landscape documents listing the controlling patents and their expiry dates, and
- UK biosimilar/EMA approval status for romiplostim biosimilars (approval timing does not always equal immediate UK market launch).
If you share the brand name you mean (or the UK patent numbers you found), I can map them to likely expiry windows and explain what would need to be cleared for a biosimilar to launch.
What to search next if you’re trying to buy romiplostim cheaper in the UK
People asking “price uk off patent” often want the practical impact:
- whether a romiplostim biosimilar is available in UK pharmacies/hospitals,
- whether NHS procurement contracts have switched to a competing product, and
- what price lists or tender outcomes show after biosimilar entry.
If you tell me whether you mean NHS supply price, private prescription price, or a specific pharmacy/discount source, I can help you target the right kind of evidence.
Quick questions to pin down the exact answer you want
1) Which exact product/brand are you referring to in the UK (the romiplostim brand name)?
2) Are you asking about patent expiry of the original (how close to “off patent”), or about whether a cheaper biosimilar is already available/approved in the UK?
3) Do you have any patent numbers (or a link) you want me to interpret?
Sources
No sources were provided in the prompt, so I can’t cite patent or market-exclusivity facts for the UK.